Search research articles
Contact Us
Filters
Showing results (651-660 of 738) with videos related to
Page
of 74
Sort By:
Clinical Pharmacology and Therapeutics
|
December 18, 2020
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
Jeroen V Koomen, Jasper Stevens, George Bakris, et al.
Diabetes, Obesity & Metabolism
|
February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
Hiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Diabetes, Obesity & Metabolism
|
April 1, 2018
Baseline characteristics and enrichment results from the SONAR trial
Hiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Circulation
|
December 29, 2006
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association
John B Buse, Henry N Ginsberg, George L Bakris, et al.
The New England Journal of Medicine
|
April 1, 2014
A controlled trial of renal denervation for resistant hypertension
Deepak L Bhatt, David E Kandzari, William W O'Neill, et al.
European Journal of Heart Failure
|
November 22, 2016
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia
Patrick Rossignol, Nicolas Girerd, George Bakris, et al.
The American Journal of Medicine
|
February 11, 2012
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease
Ali Ahmed, Gregg C Fonarow, Yan Zhang, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
December 17, 2020
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial
John P Hanrahan, Ian H de Boer, George L Bakris, et al.
Diabetes Care
|
December 29, 2006
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association
John B Buse, Henry N Ginsberg, George L Bakris, et al.
Lancet (London, England)
|
November 5, 2015
The double challenge of resistant hypertension and chronic kidney disease
Patrick Rossignol, Ziad A Massy, Michel Azizi, et al.
Page
of 74
Search research articles
Search
Showing results (651-660 of 738) with videos related to
Sort By:
Page
of 74
Clinical Pharmacology and Therapeutics
|
December 18, 2020
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
Jeroen V Koomen, Jasper Stevens, George Bakris, et al.
Diabetes, Obesity & Metabolism
|
February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
Hiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Diabetes, Obesity & Metabolism
|
April 1, 2018
Baseline characteristics and enrichment results from the SONAR trial
Hiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Circulation
|
December 29, 2006
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association
John B Buse, Henry N Ginsberg, George L Bakris, et al.
The New England Journal of Medicine
|
April 1, 2014
A controlled trial of renal denervation for resistant hypertension
Deepak L Bhatt, David E Kandzari, William W O'Neill, et al.
European Journal of Heart Failure
|
November 22, 2016
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia
Patrick Rossignol, Nicolas Girerd, George Bakris, et al.
The American Journal of Medicine
|
February 11, 2012
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease
Ali Ahmed, Gregg C Fonarow, Yan Zhang, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
December 17, 2020
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial
John P Hanrahan, Ian H de Boer, George L Bakris, et al.
Diabetes Care
|
December 29, 2006
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association
John B Buse, Henry N Ginsberg, George L Bakris, et al.
Lancet (London, England)
|
November 5, 2015
The double challenge of resistant hypertension and chronic kidney disease
Patrick Rossignol, Ziad A Massy, Michel Azizi, et al.
Page
of 74